Latest other current assets for DNLI: $35M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (March 2026), DNLI shows a other current assets of $35M. That compares with $61M in the prior-year period — down 42.2% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, DNLI's other current assets is now $35M (was $61M) — a 42.2% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Denali Therapeutics is outperforming or lagging.
Tracking DNLI's other current assets over time shows whether Denali Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $35M That compares with $61M in the prior-year period — down 42.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this other current assets page, Stockcircle has Denali Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other current assets (currently $35M) with ownership activity and broader fundamentals.
Denali Therapeutics's other current assets is $35M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.